产品号 #100-0548_C
TRα and TRβ agonist
概述
3,3',5-Triiodo-L-thyronine is a thyroid hormone, which is converted from the prohormone thyroxine via deiodination (Misiti et al.). 3,3',5-Triiodo-L-thyronine binds thyroid hormone receptors TRα and TRβ (Kd = 0.06 nM for both thyroid hormone receptors; Sandler et al.), and is essential for growth and differentiation of a variety of cell types (Misiti et al.; Shiohara et al.). 3,3',5-Triiodo-L-thyronine inhibits leucine transport by pituitary cells (IC50 = 2 μM; Yan & Hinkle). This product is supplied as the sodium salt hydrate form of the molecule.
DIFFERENTIATION
· Promotes pancreatic β cell differentiation from human pluripotent stem cells (Pagliuca et al.).
CANCER RESEARCH
· Inhibits the proliferation of pancreatic adenocarcinoma (Michienzi et al.).
Alternative Names
Liothyronine; T3; L-3,3',5-Triiodothyronine
Cell Type
Pancreatic Cells
Application
Differentiation
Area of Interest
Cancer
CAS Number
345957-19-9
Chemical Formula
C<sub>15</sub>H<sub>11</sub>I<sub>3</sub>NO<sub>4</sub> • Na • XH<sub>2</sub>O
Molecular Weight
673 g/mol
Purity
≥ 98%
Protocols and Documentation
Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.
Resources and Publications
Educational Materials (5)
Publications (6)
Generation of functional human pancreatic $\beta$ cells in vitro. Cell 2014 oct
Abstract
The generation of insulin-producing pancreatic $\beta$ cells from stem cells in vitro would provide an unprecedented cell source for drug discovery and cell transplantation therapy in diabetes. However, insulin-producing cells previously generated from human pluripotent stem cells (hPSC) lack many functional characteristics of bona fide $\beta$ cells. Here, we report a scalable differentiation protocol that can generate hundreds of millions of glucose-responsive $\beta$ cells from hPSC in vitro. These stem-cell-derived $\beta$ cells (SC-$\beta$) express markers found in mature $\beta$ cells, flux Ca(2+) in response to glucose, package insulin into secretory granules, and secrete quantities of insulin comparable to adult $\beta$ cells in response to multiple sequential glucose challenges in vitro. Furthermore, these cells secrete human insulin into the serum of mice shortly after transplantation in a glucose-regulated manner, and transplantation of these cells ameliorates hyperglycemia in diabetic mice.
Discovery of novel indane derivatives as liver-selective thyroid hormone receptor $\beta$ (TR$\beta$) agonists for the treatment of dyslipidemia. Bioorganic {\&} medicinal chemistry 2012 jun
Abstract
Thyromimetics that specifically target TR$\beta$ have been shown to reduce plasma cholesterol levels and avoid atherosclerosis through the promotion of reverse cholesterol transport in an animal model. We designed novel thyromimetics with high receptor (TR$\beta$) and organ (liver) selectivity based on the structure of eprotirome (3) and molecular modeling. We found that indane derivatives are potent and dual-selective thyromimetics expected to avoid hypothyroidism in some tissues as well as heart toxicity. KTA-439 (29), a representative indane derivative, showed the same high human TR$\beta$ selectivity in a binding assay as 3 and higher liver selectivity than 3 in a cholesterol-fed rat model.
3,3',5-Triiodo-L-thyronine inhibits ductal pancreatic adenocarcinoma proliferation improving the cytotoxic effect of chemotherapy. The Journal of endocrinology 2007 may
Abstract
The pancreatic adenocarcinoma is an aggressive and devastating disease, which is characterized by invasiveness, rapid progression, and profound resistance to actual treatments, including chemotherapy and radiotherapy. At the moment, surgical resection provides the best possibility for long-term survival, but is feasible only in the minority of patients, when advanced disease chemotherapy is considered, although the effects are modest. Several studies have shown that thyroid hormone, 3,3',5-triiodo-l-thyronine (T(3)) is able to promote or inhibit cell proliferation in a cell type-dependent manner. The aim of the present study is to investigate the ability of T(3) to reduce the cell growth of the human pancreatic duct cell lines chosen, and to increase the effect of chemotherapeutic drugs at conventional concentrations. Three human cell lines hPANC-1, Capan1, and HPAC have been used as experimental models to investigate the T(3) effects on pancreatic adenocarcinoma cell proliferation. The hPANC-1 and Capan1 cell proliferation was significantly reduced, while the hormone treatment was ineffective for HPAC cells. The T(3)-dependent cell growth inhibition was also confirmed by fluorescent activated cell sorting analysis and by cell cycle-related molecule analysis. A synergic effect of T(3) and chemotherapy was demonstrated by cell kinetic experiments performed at different times and by the traditional isobologram method. We have showed that thyroid hormone T(3) and its combination with low doses of gemcitabine (dFdCyd) and cisplatin (DDP) is able to potentiate the cytotoxic action of these chemotherapic drugs. Treatment with 5-fluorouracil was, instead, largely ineffective. In conclusion, our data support the hypothesis that T(3) and its combination with dFdCyd and DDP may act in a synergic way on adenopancreatic ductal cells.
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
